References
- Dautzenberg B. Rationale for the prevention of dissemi-nated Mycobacterium-intracellulare complex disease. Drugs 1997; 54 suppl 2: 1-7; discussion 28-29.
- Sharma AK, Khosla R, Kela AK, Mehta VL. Fluoroquinolones: Antimicrobial agents of the '90s. Ind J Pharmacol 1994; 26 (4): 249–261.
- Von-Reyn CF, Pozniak A. Infections due to the Mycobacterium auium complex (MAC). Bailliere's Clin Infect Dis 1997; 4 (1): 25–61.
- Chiodini RJ. Antimicrobial activity of rifabutin in combi-nation with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis. J Antimicrob Chemother 1991; 27 (2): 171–176.
- Strolin-Benedetti M. Inducing properties of rifabutin, and effects of the pharmacokinetics and metabolism of concomi-tant drugs. Pharmacol Res 1995; 32 (4): 177–187.
- Oesch F, Arand M, Strolin-Benedetti M, CasteIli MG, Dostert P. Inducing properties of rifampin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 1996; 37: 1111-1119.
- Strolin-Benedetti M, Dostert P. Induction and autoinduc-tion properties of rifamycin derivatives: A review of animal and human studies. Environ Health Perspect 1994; 102 (9): 101–105.
- Barriere SL, Kaatz GW, Seo SM. Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. Antimicrob Agents Chemother 1989; 33 (4): 589–590.
- McLellan RA, Drobitch RK, Monshouwer M, Renton KW. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996; 24 (10): 1134–1138.
- Nix DE, De Vito JM, Schentag JJ. Liquid chromato-graphic determination of ciprofloxacin in serum and urine. Clin Chem 1985; 31: 684–686.
- Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory. In: Swarbrick J, eds. Pharmacokinetics, 2nd ed, New York: Marcel Dekker, Inc: 1982: 409-416.
- Bailer AJ. Testing for equality of area under the curves when using destructive measurement techniques. J Pharmacokin Biopharm 1988; 16: 303–309.
- Wong PY, Zhu M, Li RC. Pharmacokinetic and phar-macodynamic interactions between intravenous ciprofloxacin and oral ferrous sulfate. J Chemother 2000; 12: 286–293.
- el-Banna HA, Abo el-Sooud K. Disposition kinetics of ciprofloxacin in lactating goats. Dtsch Tierarztl Wochenschr. 1998; 105: 35–38.
- Nix DE, Spivey JM, Norman A, Schentag JJ. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. Ann Pharmacother 1992; 26: 8–10.
- Li RC, Narang PK, Poggesi I, Strolin-Benedetti M. A. model based assessment of redistribution dependent elimina-tion and bioavailability of rifabutin. Biopharm Drug Dispos 1996; 17 (3): 223–236.
- Cheng HY, Jusko WJ. Drug redistribution and mean transit time concepts for nonlinear pharmacokinetic systems. Biopharm Drug Dispos 1991; 12 (1): 73–79.
- Strolin Benedetti M, Efthymiopoulos C, Sassella D, Moro E, Repetto M. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990; 20 (11): 1113–1119.
- Sandstrom R, Lennernas H. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats. Drug Metab Dispos 1999; 27 (8): 951–955.
- Nouws JF, Mevius DJ, Vree TB, Baars AM, Laurensen J. Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs. Vet Q 1988; 10 (3): 156–163.
- Davis RL, Koup JR, Williams-Warren J, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987; 31 (6): 915–919.
- Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethyl antipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996; 59 (6): 613–623.